US-China Deal's Patent Rules Will Boost Branded Drug Cos.
By Ryan Davis (January 16, 2020, 9:13 PM EST) -- The preliminary trade agreement signed by the U.S. and China this week should aid the branded pharmaceutical industry by creating a system to resolve patent disputes over generic drugs before they enter the market and a way to extend the life of drug patents, attorneys say.
The agreement inked Wednesday includes provisions that aim to import patent mechanisms from American law into China's system. Those include an analogue to Hatch-Waxman patent litigation, as well as patent term extensions that lengthen the life of patents to compensate for delays in patent examination and drug approval.
By signing onto the deal, China is...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!